Why the study?
Do NRF2 agonists upregulate antioxidative gene expression in cells relevant to systemic lupus erythematosus?
Observational
Do NRF2 agonists upregulate antioxidative gene expression in cells relevant to systemic lupus erythematosus?
Oxidative stress pathways in SLE patients can potentially be modulated by NRF2 agonists, suggesting a potential therapeutic target in early disease stages.
Highlights● Increased oxidative stress and decreased antioxidative capacity are present in systemic lupus erythematosus (SLE) patients● Reduced anti-oxidant gene expression in peripheral blood mononuclear cells is observed in both iSLE and SLE patients compared to healthy controls● Treatment with nuclear factor erythroid-derived 2-like 2 agonists upregulates expression of antioxidative genes in peripheral blood mononuclear cells and HaCaT keratinocytes● Oxidative stress pathways in SLE patients can potentially be modulated, which may be beneficial in early disease stages
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted an observational in Systemic lupus erythematosus (SLE) and incomplete SLE (iSLE). Nuclear factor erythroid-derived 2-like 2 (NRF2) agonists vs. Healthy controls was evaluated on Anti-oxidant gene expression and oxidative stress.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: